SCHEMBL4143905

SCHEMBL4143905

O=C(O)C(Cc1ccccc1)N1CCCCC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.71
RAB9A P51151 1/20 0.65
TSHR P16473 3/20 0.57
GAA P10253 3/20 0.57
HPGD P15428 2/20 0.57
HSD17B10 Q99714 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
ALDH1A1 P00352 2/20 0.57
PKM P14618 1/20 0.57
CYP2C19 P33261 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
MAPT P10636 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
POLB P06746 1/20 0.54
CYP2C9 P11712 1/20 0.54
PTPN7 P35236 1/20 0.54
RECQL P46063 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9096753 0.98 LMNA (0.69) LMNARAB9ATSHRGAAHPGD
SCHEMBL27910314 0.90 RAB9A (0.69) LMNARAB9ATSHRGAAHPGD
SCHEMBL6192045 0.87 RAB9A (0.62) LMNARAB9ATSHRGAAHPGD
SCHEMBL9277493 0.86 LMNA (0.71) LMNARAB9ATSHRGAAHPGD
SCHEMBL12487367 0.85 RAB9A (0.59) LMNARAB9ATSHRGAAHPGD
SCHEMBL7280926 0.83 LMNA (0.68) LMNARAB9AGAAHSD17B10NPSR1
SCHEMBL9515787 0.83 LMNA (0.72) LMNARAB9AGAAHSD17B10NPSR1
SCHEMBL19025301 0.83 LMNA (0.68) LMNARAB9ATSHRGAAHPGD
SCHEMBL4463271 0.83 LMNA (0.68) LMNARAB9AGAAHSD17B10NPSR1
SCHEMBL4434773 0.83 LMNA (0.68) LMNARAB9AGAAHSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230032216-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280 (DE) 2023-02-02 US claimed
EP-4073273-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2022-10-19 EP claimed
CN-114901837-A Interleukin-4 inducible gene 1(IL4I1) and corresponding metabolites as biomarkers for cancer 德国癌症研究公共权益基金会 2022-08-12 CN claimed
WO-2021116357-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2021-06-17 WO claimed
US-20230032216-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280 (DE) 2023-02-02 US disclosed
EP-4073273-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2022-10-19 EP disclosed
CN-114901837-A Interleukin-4 inducible gene 1(IL4I1) and corresponding metabolites as biomarkers for cancer 德国癌症研究公共权益基金会 2022-08-12 CN disclosed
WO-2021116357-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2021-06-17 WO disclosed
US-20210023034-A1 PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2021-01-28 US disclosed
WO-2019185907-A1 PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS UNIVERSITE PARIS EST CRETEIL VAL DE MARNE (FR) 2019-10-03 WO disclosed
US-20090118513-A1 Chemical Compounds ASTRAZENECA AB (SE) 2009-05-07 US disclosed
US-7495013-B2 Chemical compounds ASTRAZENECA AB (SE) 2009-02-24 US disclosed
US-20070032523-A1 Chemical compounds ASTRAZENECA AB (SE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118513-A1 Chemical Compounds CCR3, CCR1, CCR4 LMNA 3860/4885RAB9A 2189/4885TSHR 3393/4885
US-20210023034-A1 PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS IL4I1, PAH, IL4 LMNA 4429/4885RAB9A 4326/4885TSHR 3541/4885
US-20070032523-A1 Chemical compounds CCR3, CCR1, CCR4 LMNA 3992/4885RAB9A 2204/4885TSHR 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.